drugset / Trial / NCT02137993

Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia

NCT02137993

Phase 4 Completed 64 enrolled HK inno.N Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of A-prexa compared to Zyprexa in patients with schizophrenia, schizophreniform disorder and schizoaffective disorder.

Timeline

Start
2012-03
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator A-prexa Unknown 5 mg
Comparator A-prexa Unknown 10 mg
Subject Olanzapine Small molecule 5 mg
Subject Olanzapine Small molecule 10 mg